Skip to main content
SpringerLink
Log in

Lipoproteins and Diabetic Nephropathy

  • Chapter
  • First Online:
Lipoproteins in Diabetes Mellitus

Part of the book series: Contemporary Diabetes ((CDI))

  • 1717 Accesses

Abstract

Diabetic nephropathy has a significant impact on the quality of life and longevity for patients with type 1 or type 2 diabetes. Declining kidney function leads to secondary metabolic effects and adverse changes in lipoprotein metabolism, but, crucially, in patients with diabetes, the lipid abnormalities often emerge before the glomerular reserve is lost. The lipid profile is strongly correlated with albuminuria and predicts adverse outcomes, especially in the presence of other risk factors, such as poor glycemic control, obesity, and hypertension. In this chapter, we discuss the diagnostic and prognostic significance of lipoproteins and their subclasses in diabetic kidney disease and evaluate the evidence from clinical trials of lipid-lowering treatment and renal outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Afghahi H, Cederholm J, Eliasson B, Zethelius B, Gudbjörnsdottir S, Hadimeri H, Svensson MK. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes—the Swedish National Diabetes Register. Nephrol Dial Transplant. 2011;26:1236–43.

    PubMed  Google Scholar 

  2. Allen KV, Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care. 2003;26:2389–91.

    PubMed  Google Scholar 

  3. Andrews KL, Moore XL, Chin-Dusting JP. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium. Clin Exp Pharmacol Physiol. 2010;37:736–42.

    CAS  PubMed  Google Scholar 

  4. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DIAS). Am J Kidney Dis. 2005;45:485–93.

    CAS  PubMed  Google Scholar 

  5. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–34.

    CAS  PubMed  Google Scholar 

  6. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int. 2003;84:S110–2.

    Google Scholar 

  7. Attman PO, Samuelsson O, Alaupovic P. The effect of decreasing renal function on lipoprotein profiles. Nephrol Dial Transplant. 2011;26:2572–5.

    CAS  PubMed  Google Scholar 

  8. Auwerx J, Schoonjans K, Fruchart JC, Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb. 1996;3:81–9.

    CAS  PubMed  Google Scholar 

  9. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR, CKD Consensus Working Group. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010;78(8):726–36.

    PubMed  Google Scholar 

  11. Brown WV. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. Am J Cardiol. 2008;102(12A):10L–3.

    PubMed  Google Scholar 

  12. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60:219–27.

    CAS  PubMed  Google Scholar 

  13. Chaturvedi N, Fuller JF, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care. 2001;24:2071–7.

    CAS  PubMed  Google Scholar 

  14. Choudhury D, Luna-Salazar C. Preventive health care in chronic kidney disease and end-stage renal disease. Nat Clin Pract Nephrol. 2008;4:194–206.

    PubMed  Google Scholar 

  15. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.

    PubMed  Google Scholar 

  16. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the collaborative atorvastatin diabetes study (CARDS). Am J Kidney Dis. 2009;54:810–9.

    CAS  PubMed  Google Scholar 

  17. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, Drash AL, Kuller LH, Orchard TJ. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 1993;16:1376–83.

    CAS  PubMed  Google Scholar 

  18. Dautin G, Soltani Z, Ducloux D, Gautier T, Pais de Barros JP, Gambert P, Lagrost L, Masson D. Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int. 2007;72:871–8.

    CAS  PubMed  Google Scholar 

  19. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009;32:482–6.

    PubMed  Google Scholar 

  20. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O’Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54:280–90.

    CAS  PubMed  Google Scholar 

  21. DCCT. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT research group. Diabetes Care. 1992;15:886–94.

    Google Scholar 

  22. DCCT. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894–903.

    Google Scholar 

  23. DCCT. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–20.

    Google Scholar 

  24. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011;171:412–20.

    Google Scholar 

  25. Diamante. Estudio Diamante: Renal involvement in type 1 diabetes in Spain. Diabetes Res Clin Pract. 1997;38:129–37.

    Google Scholar 

  26. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988;33:917–24.

    CAS  PubMed  Google Scholar 

  27. Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145:117–24.

    CAS  PubMed  Google Scholar 

  28. Fagot-Campagna A, Nelson RG, Knowler WC, Pettitt DJ, Robbins DC, Go O, Welty TK, Lee ET, Howard BV. Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians: the Strong Heart Study. Diabetologia. 1998;41:1002–9.

    CAS  PubMed  Google Scholar 

  29. Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E. Effect of fluvastatin on renal end points in the assessment of Lescol in renal transplant (ALERT) trial. Kidney Int. 2004;66:1549–55.

    PubMed  Google Scholar 

  30. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395.

    PubMed  Google Scholar 

  31. Finne P, Reunanen A, Stenman S, Groop PH, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA. 2005;294(14):1782–7.

    CAS  PubMed  Google Scholar 

  32. Fioretto P, Mauer M. Diabetic nephropathy: diabetic nephropathy—challenges in pathologic classification. Nat Rev Nephrol. 2010;6:508–10.

    PubMed  Google Scholar 

  33. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2010;33:215–20.

    CAS  PubMed  Google Scholar 

  34. Ginsberg HN, Elam MB, Lovato LC, for The ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.

    PubMed  Google Scholar 

  35. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2004;47:1020–8.

    CAS  PubMed  Google Scholar 

  36. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22:9–15.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab. 2005;1(2):100–10.

    CAS  PubMed  Google Scholar 

  38. Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, Mäkinen VP, Rosengård-Bärlund M, Saraheimo M, Hietala K, Heikkilä O, Forsblom C, FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651–8.

    CAS  PubMed  Google Scholar 

  39. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–76.

    PubMed  Google Scholar 

  40. Gröne HJ, Walli AK, Gröne EF. Arterial hypertension and hyperlipidemia as determinants of glomerulosclerosis. Clin Investig. 1993;71:834–9.

    PubMed  Google Scholar 

  41. Hadjadj S. Duly-Bouhanick B, Bekherraz A, BrIdoux F, Gallois Y, Mauco G, Ebran J, Marre M. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab. 2004;30:43–51.

    Google Scholar 

  42. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024–31.

    CAS  PubMed  Google Scholar 

  43. Holdaas H, Fellström B, Cole E, Nyberg G, Olsson A, Pedersen T, Madsen S, Grönhagen‐Riska C, Neumayer HH, Maes B. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–36.

    CAS  PubMed  Google Scholar 

  44. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–9.

    CAS  PubMed  Google Scholar 

  45. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parcing HH. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004;328:1105.

    PubMed  Google Scholar 

  46. Huskey J, Lindenfeld J, Cook T, Targher G, Kendrick J, Kjekshus J, Pedersen T, Chonchol M. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian simvastatin survival study (4S). Atherosclerosis. 2009;205:202–6.

    CAS  PubMed  Google Scholar 

  47. Ikewaki K, Schaefer JR, Frischmann ME. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2615–22.

    CAS  PubMed  Google Scholar 

  48. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003;64:817–28.

    CAS  PubMed  Google Scholar 

  49. Jensen T, Stender S, Deckert T. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin dependent) diabetic patients with increased urinary albumin excretion. Diabetologia. 1988;31:142–5.

    CAS  PubMed  Google Scholar 

  50. Jones SL, Close CF, Mattock MB, Jarret RJ, Keen H, Viberti GC. Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ. 1989;298:487–90.

    CAS  PubMed  Google Scholar 

  51. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84.

    CAS  PubMed  Google Scholar 

  52. Kahri J, Groop PH, Elliott T, Viberti G, Taskinen MR. Plasma cholesteryl ester transfer protein and its relationship to plasma lipoproteins and apolipoprotein A-I containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy. Diabetes Care.1994;17:412–419.

    Google Scholar 

  53. Kastarinen H, Hörkkö S, Kauma H, Karjalainen A, Savolainen MJ, Kesäniemi YA. Low-density lipoprotein clearance in patients with chronic renal failure. Nephrol Dial Transplant. 2009;24:2131–5.

    CAS  PubMed  Google Scholar 

  54. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–7.

    CAS  PubMed  Google Scholar 

  55. Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;2011(21):120–3.

    Google Scholar 

  56. Keane WF, Kasiske BL, O’Donnell MP, Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis. 1991;17:38–42.

    CAS  PubMed  Google Scholar 

  57. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.

    CAS  PubMed  Google Scholar 

  58. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care. 2007;30(3):707–12.

    CAS  PubMed  Google Scholar 

  59. Kilpatrick ES, Rigby AS, Atkin SL. The diabetes control and complications trial: the gift that keeps giving. Nat Rev Endocrinol. 2009;5(10):537–45.

    PubMed  Google Scholar 

  60. Kronenberg F. Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr. 2005;15:195–203.

    PubMed  Google Scholar 

  61. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403–25.

    PubMed  Google Scholar 

  62. Lin J, Hu FB, Rimm EB, Rifai N, Curhan GC. The association of serum lipids and inflammatory biomarkers with renal function in men with type 2 diabetes mellitus. Kidney Int. 2006;69(2):336–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Lin J, Hu FB, Mantzoros C, Curhan GC. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia. 2010;53(2):263–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, Cooper JD, Edge J, Neil A, Shield J, Widmer B, Todd JA, Dunger DB. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009;32:658–63.

    CAS  PubMed  Google Scholar 

  65. Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, Bandinelli S, Standl E, Kofinis A, Fuller JH. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabetic Med. 2001;18:59–67.

    Google Scholar 

  66. Mulec H, Johnsen SA, Wiklund O, Björck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22:196–201.

    CAS  PubMed  Google Scholar 

  67. Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti-inflammatory effects of high density lipoproteins. Curr Med Chem. 2009;16:667–75.

    CAS  PubMed  Google Scholar 

  68. Mäkinen V, Forsblom C, Thorn LM, Wadén J, Gordin D, Heikkilä O, Hietala K, Kyllönen L, Kytö J, Rosengård-Bärlund M, Saraheimo M, Tolonen N, Parkkonen M, Kaski K, Ala-Korpela M, Groop P. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes. 2008;57:2480–7.

    PubMed  Google Scholar 

  69. Mäkinen V-P, Tynkkynen T, Soininen P, Forsblom C, Peltola T, Kangas AJ, Groop P-H, Ala-Korpela M. Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics. 2011;8(3):369–75.

    PubMed Central  PubMed  Google Scholar 

  70. Mäkinen VP, et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes. J Proteome Res. 2012;11(3):1782–90.

    PubMed  Google Scholar 

  71. Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic renal failure. Am J Nephrol. 2009;30:147–54.

    CAS  PubMed  Google Scholar 

  72. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670–5.

    PubMed  Google Scholar 

  73. Nakajima K, Nakano T, Tokita Y, Nagamine T, Inazu A, Kobayashi J, Mabuchi H, Stanhope KL, Havel PJ, Okazaki M, Ai M, Tanaka A. Postprandial lipoprotein metabolism: VLDL vs. chylomicrons. Clin Chim Acta. 2011;412:1306–18.

    CAS  PubMed Central  PubMed  Google Scholar 

  74. Natali A, Pucci G, Boldrini B, Schillaci G. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol. 2009;22(1):29–38.

    PubMed  Google Scholar 

  75. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;2, CD007784.

    PubMed  Google Scholar 

  76. Nikkilä EA, Hormila P. Serum lipids and lipoproteins in insulin-treated diabetes: demonstrations of increased high-density lipoprotein concentrations. Diabetes. 1978;27:1078–86.

    PubMed  Google Scholar 

  77. Orchard TJ, Chang Y-F, Ferrel RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int. 2002;62:963–70.

    CAS  PubMed  Google Scholar 

  78. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality in type 2 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53:2312–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48(3–4):171–80.

    CAS  PubMed  Google Scholar 

  80. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006;17:412–7.

    CAS  PubMed  Google Scholar 

  81. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–27.

    CAS  PubMed  Google Scholar 

  82. Parving HH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens. 1990;8:S187–91.

    CAS  Google Scholar 

  83. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–93.

    CAS  PubMed  Google Scholar 

  84. Peric-Golia L, Peric-Golia M. Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis. 1983;46:57–65.

    CAS  PubMed  Google Scholar 

  85. Postma MJ, de Zeeuw D. The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2009;24(10):2975–83.

    PubMed  Google Scholar 

  86. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003;14:S315–20.

    CAS  PubMed  Google Scholar 

  87. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090–100.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30:2523–8.

    PubMed  Google Scholar 

  89. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998–1004.

    CAS  PubMed  Google Scholar 

  90. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, the UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes. Diabetes. 2006;55:1832–9.

    CAS  PubMed  Google Scholar 

  91. Ridker PM, Macfadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention—an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266–73.

    CAS  PubMed  Google Scholar 

  92. Rossi MCE, Nicolucci A, Pellegrini F, Comaschi M, Ceriello A, Cucinotta D, Giorda C, Valentini U, Vespasiani G, De Cosmo S. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) study. Nephrol Dial Transplant. 2008;23:1278–84.

    Google Scholar 

  93. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010;21:229–38.

    CAS  PubMed Central  PubMed  Google Scholar 

  94. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713–21.

    CAS  PubMed  Google Scholar 

  95. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908–15.

    CAS  PubMed  Google Scholar 

  96. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59:3216–22.

    CAS  PubMed  Google Scholar 

  97. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–91.

    CAS  PubMed  Google Scholar 

  98. Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol. 2011;7(3):145–54.

    PubMed  Google Scholar 

  99. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–16.

    CAS  PubMed  Google Scholar 

  100. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets I. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–9.

    CAS  PubMed  Google Scholar 

  101. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK, Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83:870–9.

    CAS  PubMed  Google Scholar 

  102. Stadler M, Auinger M, Anderwald C, Kästenbauer T, Kramar R, Feinböck C, Irsigler K, Kronenberg F, Prager R. Long-term mortality and incidence of renal dialysis and transplantation in type 1 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:3814–20.

    CAS  PubMed  Google Scholar 

  103. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–51.

    CAS  PubMed  Google Scholar 

  104. Sukhija R, Bursac Z, Kakar P, Fink L, Fort C, Satwani S, Aronow WS, Bansal D, Mehta JL. Effect of statins on the development of renal dysfunction. Am J Cardiol. 2008;101:975–9.

    CAS  PubMed  Google Scholar 

  105. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease. Int J Cardiol. 2011;152:242–4.

    PubMed  Google Scholar 

  106. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733–49.

    PubMed  Google Scholar 

  107. Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Cooper ME, Taskinen MR, Viberti G, Groop PH. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care. 2006;29(2):317–22.

    CAS  PubMed  Google Scholar 

  108. Thorn LM, Forsblom C, Wadén J, Saraheimo M, Tolonen N, Hietala K, Groop PH, Finnish Diabetic Nephropathy Study Group. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2009;32(5):950–2. Epub 2009 Feb 5.

    PubMed  Google Scholar 

  109. Tolonen N, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Saraheimo M, Heikkilä O, Pettersson-Fernholm K, Taskinen MR, Groop PH, FinnDiane Study Group. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia. 2008;51(1):12–20.

    CAS  PubMed  Google Scholar 

  110. Tolonen N, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Saraheimo M, Feodoroff M, Mäkinen VP, Gordin D, Taskinen MR, Groop PH, FinnDiane Study Group. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia. 2009;52(12):2522–30.

    CAS  PubMed  Google Scholar 

  111. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–8.

    CAS  PubMed  Google Scholar 

  112. Tseng CH. Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kidney Int. 2005;67:1547–53.

    Google Scholar 

  113. Vannini P, Ciavarella A, Flammini M, Bargossi AM, Forlani G, Borgnino LC, Orsoni G. Lipid abnormalities in insulin-dependent diabetic patients with albuminuria. Diabetes Care. 1984;7:151–4.

    Google Scholar 

  114. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial. 2009;22:644–51.

    PubMed Central  PubMed  Google Scholar 

  115. Vergès B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis. 2010;211:353–60.

    PubMed  Google Scholar 

  116. Verhoye E, Langlois MR, Asklepios Investigators. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med. 2009;47:128–37.

    CAS  PubMed  Google Scholar 

  117. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–49.

    CAS  PubMed  Google Scholar 

  118. Yang X, So WY, Ma R, Ko G, Kong A, Lam C, Ho CS, Cockram C, Chow C-C, Tong P, Chan J. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes — the Hong Kong Diabetes Registry. Nephrol Dial Transplant. 2008;23:2834–40.

    Google Scholar 

  119. Yishak A, Costacou T, Virella G, Zgibor J, Fried L, Walsh M, Evans RW, Lopes-Virella M, Kagan VE, Otvos J, Orchard TJ. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006;21:93–100.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Folkhälsan Research Center, Folkhälsan Institute of Genetics, Biomedicum Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland

    Ville-Petteri Mäkinen, Nina Tolonen & Per-Henrik Groop M.D., D.M.Sc.

  2. Department of Medicine, Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland

    Ville-Petteri Mäkinen, Nina Tolonen & Per-Henrik Groop M.D., D.M.Sc.

  3. Baker IDI Heart & Diabetes Institute, Melbourne, VIC, Australia

    Per-Henrik Groop M.D., D.M.Sc.

Authors
  1. Ville-Petteri Mäkinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nina Tolonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Per-Henrik Groop M.D., D.M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Per-Henrik Groop M.D., D.M.Sc. .

Editor information

Editors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

    Alicia J. Jenkins

  2. College of Medicine, University of Illinois, Peoria, Illinois, USA

    Peter P. Toth

  3. Section of Endocrinology and Diabetes Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

    Timothy J. Lyons

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mäkinen, VP., Tolonen, N., Groop, PH. (2014). Lipoproteins and Diabetic Nephropathy. In: Jenkins, A., Toth, P., Lyons, T. (eds) Lipoproteins in Diabetes Mellitus. Contemporary Diabetes. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-7554-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7554-5_14

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4614-7553-8

  • Online ISBN: 978-1-4614-7554-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation